Memantine Hydrochloride Tablet
Product Images NDC 50090-7348

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 50090-7348). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907348)

Label for memantine hydrochloride 5 mg coated tablets by A-S Medication Solutions. The label indicates oral tablets with memantine hydrochloride as the active ingredient, with 60 tablets in the package. It includes storage instructions and a lot number, along with the product NDC 50090-7348.*

FDA Label Image

Memantinetabs-figure6 (Memantinetabs Figure6)

A cumulative percentage graph showing patient response to treatment with memantine hydrochloride tablets plus donepezil compared to placebo plus donepezil. The x-axis represents ADCS-ADL change from baseline, while the y-axis shows the cumulative percentage of patients. Two curves are plotted: one with square markers for placebo/donepezil and one with circular markers for memantine hydrochloride tablets/donepezil.*

FDA Label Image

Memantinetabscamberlogo (Memantinetabscamberlogo)

FDA Label Image

Memantinetabsfigure1 (Memantinetabsfigure1)

Line graph showing mean change from baseline in ADCS-ADL score over 28 weeks of treatment comparing memantine hydrochloride tablets to placebo. The y-axis represents the mean change, with clinical improvement indicated above zero and clinical decline below. The graph shows memantine hydrochloride maintaining scores closer to baseline, while placebo shows greater decline.*

FDA Label Image

Memantinetabsfigure2 (Memantinetabsfigure2)

A cumulative percentage of patients line graph comparing ADCS-ADL change from baseline among three groups: Placebo, Memantine Hydrochloride, and Tablets. The x-axis represents ADCS-ADL change from baseline, and the y-axis shows the cumulative percentage of patients, ranging from 0 to 100%. Lines for each group are plotted to show their distribution over the change scale.*

FDA Label Image

Memantinetabsfigure3 (Memantinetabsfigure3)

A line graph showing the mean change from baseline in SIB score over 28 weeks of treatment with memantine hydrochloride tablets versus placebo. The x-axis represents weeks of treatment, and the y-axis shows mean change in SIB score. The graph includes error bars for standard error of the mean and indicates clinical improvement and decline thresholds.*

FDA Label Image

Memantinetabsfigure4 (Memantinetabsfigure4)

A cumulative percentage graph of patients plotting SIB Change from Baseline on the x-axis against Weeks of Treatment on the secondary x-axis. Two lines are shown: one for Placebo and the other for Memantine Hydrochloride Tablets, illustrating comparative response over time in this clinical context.*

FDA Label Image

Memantinetabsfigure5 (Memantinetabsfigure5)

A line graph showing mean change from baseline in ADCS-ADL score over 24 weeks of treatment comparing memantine hydrochloride tablets with donepezil versus placebo with donepezil. The y-axis represents mean change with clinical improvement and decline markers, while the x-axis shows weeks of treatment. Two lines plot the score changes, with memantine showing less decline than placebo over time.*

FDA Label Image

Memantinetabsfigure7 (Memantinetabsfigure7)

A line graph showing mean change from baseline in SIB score over 24 weeks of treatment comparing placebo/donepezil and memantine hydrochloride tablets/donepezil. The y-axis measures the mean change (± SEM), with positive values indicating clinical improvement and negative values indicating clinical decline. Memantine hydrochloride tablets/donepezil show an increase in mean SIB score, peaking around week 12, while placebo/donepezil remains near baseline or declines over time.*

FDA Label Image

Memantinetabsfigure8 (Memantinetabsfigure8)

A cumulative distribution plot comparing the percentage of patients with SIB (Severe Impairment Battery) score changes from baseline. The graph contrasts memantine hydrochloride tablets combined with donepezil versus placebo with donepezil, showing lines and markers illustrating cumulative patient response across a range of SIB change values.*

FDA Label Image

Memantinetabsstructure (Memantinetabsstructure)

Chemical structure of memantine hydrochloride showing the molecular framework with labeled amino group (NH2), two methyl groups (CH3), and hydrochloride (HCl) component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.